中文名称: | A-804598 | ||||
---|---|---|---|---|---|
英文名称: | A 804598 | ||||
别名: | A-804598 N-Cyano-N′′-[(1S)-1-phenylethyl]-N′-5-quinolinyl-guanidine | ||||
CAS No: | 1125758-85-1 | 分子式: | C19H17N5 | 分子量: | 315.37 |
CAS No: | 1125758-85-1 | ||||
分子式: | C19H17N5 | ||||
分子量: | 315.37 |
基本信息
产品编号: |
A60003 |
||||
产品名称: |
A 804598 |
||||
CAS: |
1125758-85-1 |
储存条件 |
粉末 |
2-8℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
6个月 |
||
分子量: |
315.37 |
-20℃ |
1个月 |
||
化学名: |
N-Cyano-N′′-[(1S)-1-phenylethyl]-N′-5-quinolinyl-guanidine N-Cyano-N′′-[(1S)-1-phenylethyl]-N′-5-quinolinyl-guanidine |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
63 mg/mL (199.76 mM) |
|||
Ethanol |
6 mg/mL (19.02 mM) |
||||
Water |
Insoluble |
||||
体内(现配现用): |
请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照In Vitro⽅式配制澄清的储备液,再依次添加助溶剂:为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的⼯作液,建议您现⽤现配,当天使⽤;以下溶剂前显⽰的百分⽐是指该溶剂在您配制终溶液中的体积占⽐;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的⽅式助溶。 1.请依序添加每种溶剂:10% DMSO 40% PEG300 5% Tween-80 45% saline Solubility:≥2.5mg/mL(7.93mM);Clear solution 2.请依序添加每种溶剂:10% DMSO 90%(20% SBE-β-CD in saline) Solubility:2.5mg/mL(7.93mM);Clear solution;Need ultrasonic 3.请依序添加每种溶剂:10% DMSO 90% corn oil Solubility:≥2.5mg/mL(7.93mM);Clear solution |
||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
3.1709mL |
15.8544mL |
31.7088mL |
5mM |
0.6342mL |
3.1709mL |
6.3418mL |
10mM |
0.3171mL |
1.5854mL |
3.1709mL |
生物活性
产品描述 |
一种强力的竞争性和选择性的P2X7受体拮抗剂。 |
|
靶点 |
IC50:9nM (mouse P2X7 receptor),10nM (rat P2X7 receptor),11nM (human P2X7 receptor) |
|
体外研究 |
Pre-incubation with A-804598 (0.1-10μM;1 hour) significantly attenuates BzATP-induced cell loss in a concentrationdependent manner.3μM A-804598 exhibits the greatest protective effect against BzATP-induced cytotoxicity. Cell Cytotoxicity Assay |
|
Cell Line: |
microglial cell |
|
Concentration: |
0.1,0.3,1,3,10μM |
|
Incubation Time: |
1 hour |
|
Result: |
Protected against BzATP-induced cytotoxicity in both inactivated and activated microglia. |
|
体内研究 |
A chroni treatment with A-804598 (intraperitoneal injection;30mg/kg;five times a week) decreases the expression of LC3B-II and SQSTM1/p62 in lumbar spinal cord at end stage of disease. |
|
Animal Model: |
Adult B6.Cg-Tg (SOD1-G93A) 1Gur/J female mice |
|
Dosage: |
30mg/kg |
|
Administration: |
Intraperitoneal injection;five times a week |
|
Result: |
Decreased SQSTM1/p62 expression. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )